BACKGROUND: Polymorphonuclear leukocytes (PMNs) must traverse endogenous chemotactic gradients (interleukin 8 [IL-8]) before reaching target chemoattractants (fMLP [N-formylmethionine-leucine-phenylalanine], C5a) produced at a site of bacterial infection. Complement receptor 3 (CR3; CD11b/CD18) contains 2 distinct binding sites, one that mediates adhesion and a lectin-like domain (LLD) that binds polysaccharides of microbial origin. This laboratory previously reported an increase in the chemotactic capacity of PMNs toward fMLP upon ligation of the CR3 LLD with beta-glucan, a CR3 agonist. Current studies sought to determine the effect of beta-glucan on PMN navigation toward other chemoattractants alone and in a competing chemotactic environment. METHODS: Migration was assessed by serum agarose overlay with the use of chambered slides containing or not, beta-glucan. Migration of human PMNs at 37 degrees C for 2 hours was evaluated toward C5a or IL-8 alone and in competing gradients. Selected groups were treated with anti-CR3-blocking antibodies. The number of chemotactic cells was quantified by microscopy. RESULTS: beta-glucan significantly enhanced chemotaxis toward C5a and suppressed that toward IL-8 in a CR3-dependent fashion. In the competing chemotactic gradient assays (C5a vs IL-8), beta-glucan further enhanced migration toward C5a while not affecting that toward IL-8. CONCLUSIONS: beta-glucan selectively upregulates PMN chemotaxis toward C5a while suppressing chemotaxis toward IL-8. Copyright 2004 Elsevier Inc.
BACKGROUND: Polymorphonuclear leukocytes (PMNs) must traverse endogenous chemotactic gradients (interleukin 8 [IL-8]) before reaching target chemoattractants (fMLP [N-formylmethionine-leucine-phenylalanine], C5a) produced at a site of bacterial infection. Complement receptor 3 (CR3; CD11b/CD18) contains 2 distinct binding sites, one that mediates adhesion and a lectin-like domain (LLD) that binds polysaccharides of microbial origin. This laboratory previously reported an increase in the chemotactic capacity of PMNs toward fMLP upon ligation of the CR3 LLD with beta-glucan, a CR3 agonist. Current studies sought to determine the effect of beta-glucan on PMN navigation toward other chemoattractants alone and in a competing chemotactic environment. METHODS: Migration was assessed by serum agarose overlay with the use of chambered slides containing or not, beta-glucan. Migration of human PMNs at 37 degrees C for 2 hours was evaluated toward C5a or IL-8 alone and in competing gradients. Selected groups were treated with anti-CR3-blocking antibodies. The number of chemotactic cells was quantified by microscopy. RESULTS:beta-glucan significantly enhanced chemotaxis toward C5a and suppressed that toward IL-8 in a CR3-dependent fashion. In the competing chemotactic gradient assays (C5a vs IL-8), beta-glucan further enhanced migration toward C5a while not affecting that toward IL-8. CONCLUSIONS:beta-glucan selectively upregulates PMN chemotaxis toward C5a while suppressing chemotaxis toward IL-8. Copyright 2004 Elsevier Inc.
Authors: Bing Li; Daniel J Allendorf; Richard Hansen; Jose Marroquin; Daniel E Cramer; Claire L Harris; Jun Yan Journal: Cancer Res Date: 2007-08-01 Impact factor: 12.701
Authors: Bing Li; Daniel Cramer; Stephanie Wagner; Richard Hansen; Chelsea King; Shelly Kakar; Chuanlin Ding; Jun Yan Journal: Clin Immunol Date: 2007-06-14 Impact factor: 3.969
Authors: Matthias Kelm; Sylvain Lehoux; Veronica Azcutia; Richard D Cummings; Asma Nusrat; Charles A Parkos; Jennifer C Brazil Journal: FASEB J Date: 2019-12-23 Impact factor: 5.191